disclosures
play

Disclosures None RAIN Conference 2015 Case Presentations Maulik - PowerPoint PPT Presentation

2/13/2015 Disclosures None RAIN Conference 2015 Case Presentations Maulik Shah, MD UCSF Neurohospitalist Division Case #1, continued Case #1: Rapidly progressive weakness He was at home with family stable on pain 18 year old man


  1. 2/13/2015 Disclosures • None RAIN Conference 2015 Case Presentations Maulik Shah, MD UCSF Neurohospitalist Division Case #1, continued Case #1: Rapidly progressive weakness • He was at home with family stable on pain • 18 year old man who developed diarrheal illness medications until October, when he was taken and colitis while traveling in India in July to Emergency Department with worsening • GI illness improved but then he developed headache and high fever persistent and diffuse joint pains, oral ulcers, hair • He was admitted and the next day started to loss, frequent headache, and intermittent fever complain of tingling and weakness in his feet • Upon return to US, had work-up for tropical than quickly progressed to his thighs over few diseases which was unrevealing hours • Labs notable for new normocytic anemia and ESR • Noted to be areflexic > 100 1

  2. 2/13/2015 Question 1 Lumbar Puncture Results How would you manage this patient at this time? • The patient had lumbar puncture at that time A. Start antibiotics (Vancomycin and Ceftriaxone) at meningeal dosing and • Normal opening pressure 30% Acyclovir • WBC 21 (61% neutrophils) 26% B. Start antibiotics, Acyclovir, and 21% • Glucose 52 (serum 126) 18% steroids • Protein 388 C. Start high dose steroids 4% D. Start IVIg g s S . . d I . . V C E. Obtain urgent EMG/NCS . v i i I N m o o r t / o l r c e a G c y t n s t M c S a A e E V s t ( , o n s d s c e c i i t h g t o g r o u b i i b i h n i i t t i t n r a n a a b t a t t S O t r r a a t S t S Case #1, continued Initial Neurologic Examination • The patient was started on antibiotics and • Intubated on ventilator in the ICU Acyclovir • MENTAL STATUS awake and alert, able to shake head to answer questions and follows midline commands • Over next 24 hours, his flaccid weakness and • CRANIAL NERVES vfftc, PERRL, full extra-ocular tingling progressed to involve all limbs muscles, full facial strength with eyelid closure, and • He developed respiratory failure requiring able to lift his head out of bed intubation as well as worsening anemia • MOTOR flaccid paralysis of arms and legs requiring transfusion • SENSORY absent over limbs, trunk, buttocks and back but intact over upper neck and face • He was then started on IVIg and was • COORD no tremor or involuntary movements transferred to UCSF Neurology service • REFLEXES absent throughout in limbs with intact jaw jerk 2

  3. 2/13/2015 Question #2 Wh at diagnostic testing would you pursue at this time? 60% A. MRI Cervical and Total Spine B. Repeat lumbar puncture C. Urgent EMG/NCS 26% D. CT Cervical Spine 8% 7% S e e C n . r . . u N i p l t / S a c G t n M l o u a T c p E i v d r n a t r n e a b e C l m g a T c u r C U i l v t r e a e C p I e R R M Question #3 Repeat Lumbar Puncture Which diagnosis is LEAST likely at this time given neurologic examination, CSF and imaging • WBC 198 (76% neutrophils) findings? • Glucose 26 A. Neuromyelitis optica (NMO) 36% • Protein 233 28% B. SLE Myelitis C. Acute Disseminated 14% 13% • CSF gram stain negative Encephalomyelitis 10% • Prior CSF and blood cultures negative to date D. West Nile Encephalomyelitis s s E. VZV Myelitis ) i s i O t i t i . t i M l . i l e l e c . e y y N n y M M ( E m a d o V c E L e l Z t i a S t V p a h o n p i e s m i c t e n i l s E e s y e i m D l i e N o r t t u u s e c e A N W 3

  4. 2/13/2015 MRI of Spine Additional Serologic Work-up CSF Analysis: Elevated WBC or IgG index or OCB • HIV negative Vascular (Ischemic) • ESR > 100 Dural AV fistula Vitamin B12 deficiency • ANA 1:160 Nitrous Oxide toxicity Multple Sclerosis HSV Lymphoma Vitamin E deficiency • DS-DNA titers > 1:10,000 titer Neuromyelitis optica CMV Intramedullary tumors: Copper deficiency ADEM EBV -Ependymoma Adrenoleukodystrophy / • Low C3 and C4 complement levels SLE VZV -Astrocytoma Adrenomyeloneuropathy Sjogren’s HIV -Hemangioblastoma HIV vacuolar myelopathy • Normal lupus anti-coagulation and anti- Sarcoid WNV (AHC) Paraneoplastic Vasculitis HTLV (not always phospholipid antibody panels inflammatory) Enterovirus 71 Fungal: cocci, histo Tuberculosis • CSF HSV, VZV PCR negative Mycoplasma Lyme Syphilis SLE Myelitis Grey and White Myelitis • Occurs in 1% of patients with neuropsychiatric SLE, most commonly in women • Can be the first presentation of SLE • Longitudinally extensive > 3 segments in 70% of cases, often holo-cord involvement • In one study of 75 patients with neuropsychiatric SLE, only one had +NMO antibody – Patient had longitudinally extensive myelitis – Increased incidence of +NMO antibody in SLE and other rheumatologic disorders in patients with myelitis and/or optic neuritis • Two clinical phenotypes in terms of presentation 4

  5. 2/13/2015 SLE Myelitis: Clinical Subtypes • Grey matter myelitis: rapid onset weakness (often within 6 hours) with LMN findings of flaccidity and hypo-reflexia on presentation – First symptom was usually acute urinary retention – LMN signs persist over time • White matter myelitis: UMN findings of spasticity and hyper-reflexia Question #4 SLE Myelitis: Treatment How would treat this patient at this time? • No randomized controlled trials, most data from A. High dose steroids and Cyclophosphamide outcomes of case series for next few months, then Azathioprine • European League Against Rheumatism long-term 37% recommendations B. Plasmapheresis and prolonged steroid taper 27% – Early high-dose steroids and ideally 24% C. High dose steroids and then Rituximab if Cyclophosphamide (although LP will often be NMO returns positive concerning for infection) 13% – Anticoagulation in those with +APLS antibodies D. High dose steroids and Cyclophosphamide – Reasonable to use plasmapheresis in severe cases for next few months, then Rituximab if NMO returns negative • Several case reports suggest efficacy of Rituximab . . . . . . . C . . . C . o . t d r d n p d n n – NMO association and recurrent myelitis a d a a s n s a s d d i d i o s i o i o r s r e e r e e s t r s t e t h s e e s p e s o s o a o d m d d h h s h g a g i l g i H P H H i 5

  6. 2/13/2015 Prognosis: Grey vs. White Case #2: An attack of ataxia • Grey matter myelitis: despite getting more immune • 84 year old woman with rheumatic heart disease therapy, mean EDSS 8.0 (range 8-10) and hypertension who experienced abrupt onset – Irreversible paraplegia of difficulty holding playing cards – Wheelchair bound • Her voice then became slurred and slowed and • White matter myelitis mean EDSS 6.0 (range 2-10) over next few hours she was unable to walk – Dependent on ambulatory assistive device to walk without support • Went to Emergency Department and was felt to • Patient was treated with IV steroids and Cyclophosphamide have an acute stroke although MRI Brain showed • Our patient’s arm strength improved and he was extubated no evidence of ischemia • Continued on six months of Cyclophosphamide and then Azathioprine • Discharged home with adjustment of antiplatelet • Remains paraplegic with distal hand weakness and and initiation of statin bowel/bladder dysfunction Case #2, continued • At home, she had progressive symptoms – Double vision – Recurrent falls, unable to ambulate even with walker • Additional review of symptoms – 25 lb weight loss due loss of appetite – URI while visiting Hawaii two months prior Patient provided permission for video to be used for teaching purposes • 6

  7. 2/13/2015 Question #5 Lumbar Puncture Given patient’s examination, the imaging shown has most definitively ruled out which of the • Clinical examination was felt to be most following etiologies? consistent with pan-cerebellopathy A. Acute or subacute cerebellar stroke • CSF was collected as next part of diagnostic work- up and revealed B. Auto-immune cerebellitis 82% – WBC 30 (81% lymphs) C. Post-infectious viral cerebellitis – Protein 130 – Glucose 78 D. Creutzfeldt-Jakob Disease E. Miller Fisher variant AIDP • CSF cytology and flow cytometry negative 6% 5% 4% 3% • CSF EBV, HSV, VZV PCR negative s e . . s P . t i . D . i . a e l b e I b l e A e s e b r i t r e D n e c e r b a c e l i a o r e c k a t r e v i a v u n J c - r a u s t e u d h b m o u l s m i e i s t f F c z r - i e t r o o u e f e t n e l l u i i t A - r M u t C s c o A P 7

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend